Company Overview and News

1
Novartis and Other Drug Stocks With FDA Catalysts in April

2018-04-10 zacks
Last year turned out to be pretty good for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 46 novel drugs, easily surpassing 2016’s total tally of 22.

 
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs

2018-04-04 globenewswire
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Steve Caffé, M.D., as Head of Regulatory Affairs. Dr. Caffé brings to CRISPR a 25-year track record in global product development and regulatory affairs, having held senior leadership positions at many leading biotechnology and pharmaceuticals companies.

 
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017

2018-04-02 marketwired
BALTIMORE, MD--(Marketwired - April 02, 2018) - Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash and cash equivalents of $2.5 million, accounts receivable of $3.3 million, and escrowed receivable of $3.

1
Cerecor Appoints Peter Greenleaf as Chief Executive Officer

2018-03-28 marketwired
BALTIMORE, MD--(Marketwired - March 28, 2018) - Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company's board since May 2017. He brings to Cerecor over two decades of biopharmaceutical experience, having most recently served as Chairman and CEO of Sucampo Pharmaceuticals and led the company's acquisition by Mallinckrodt Pharmaceuticals for $1.

3
Synergy: The Illusion Of Success Or Grounded Potential? A SWOT Analysis

2018-03-20 seekingalpha
With the FDA approval of Trulance for both CIC and IBS-C, Synergy is strategically positioned in a nascent prescription product market that is growing organically.

1
Mallinckrodt: Can The Upside Trump This Pertinent Risk?

2018-03-01 seekingalpha
Nevertheless, a key signal in the balance sheet (as keenly spotted by President of Business Development Abelardo Fraga) prompted us to stay neutral on Mallinckrodt.

 
Mallinckrodt (MNK) Up on Earnings and Revenues Beat in Q4

2018-02-28 zacks
Following encouraging fourth-quarter 2017 results, shares of Mallinckrodt Public Limited Company (MNK - Free Report) moved up 15.3%.

 
SCMP / Sucampo Pharmaceuticals, Inc. 15-12B

2018-02-23 sec.gov
15-12B     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 15     CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33609     SUCAMPO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)     805 King Farm Blvd, Suite 550 Rockville, Maryland 2085

11
Tracking John Paulson's Paulson & Company Portfolio - Q4 2017 Update

2018-02-20 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s US stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 02/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q3 2017.

 
SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D/A (Activist Investment)

2018-02-15 sec.gov
SC 13D/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

 
SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D/A (Activist Investment)

2018-02-15 sec.gov
SC 13D/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number)   David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicatio

 
SCMP / Sucampo Pharmaceuticals, Inc. / Kuno Sachiko - SC 13D/A (Activist Investment)

2018-02-15 sec.gov
SC 13D/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number) David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

 
SCMP / Sucampo Pharmaceuticals, Inc. / Ueno Ryuji - SC 13D/A (Activist Investment)

2018-02-15 sec.gov
SC 13D/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Sucampo Pharmaceuticals, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 864909106 (CUSIP Number)   David A. Rivard, Esquire McGuireWoods LLP 800 East Canal Street Richmond, VA 23219 (804) 775-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communicatio

 
SCMP / Sucampo Pharmaceuticals, Inc. / LSV ASSET MANAGEMENT - 3G (Passive Investment)

2018-02-13 sec.gov
SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUCAMPO PHARMACEURICALS, INC. CENTRAL INDEX KEY: 0001365216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 30-0520478 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 001-33609 FILM NUMBER: BUSINESS ADDRESS: STREET 1: 2700 N. FIRST STREET STREET 2: CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 4089643500 MAIL ADDRESS: STREET 1: 2700

 
SCMP / Sucampo Pharmaceuticals, Inc. / LSV ASSET MANAGEMENT - 3G (Passive Investment)

2018-02-13 sec.gov
SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SUCAMPO PHARMACEURICALS, INC. CENTRAL INDEX KEY: 0001365216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 30-0520478 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 001-33609 FILM NUMBER: BUSINESS ADDRESS: STREET 1: 2700 N. FIRST STREET STREET 2: CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 4089643500 MAIL ADDRESS: STREET 1: 2700

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 864909106